PowerLook Density Assessment
Objective, reliable, consistent breast density scoring
Software · Cloud SaaSCompany source
Company profile
About ICAD
iCAD, Inc. is a global leader in clinically proven AI-powered cancer detection solutions, specializing in breast health imaging. Now part of DeepHealth, a RadNet subsidiary following acquisition in July 2025, iCAD has over 25 years of experience delivering deep-learning AI solutions for medical imaging. The company's flagship ProFound Breast Health Suite comprises three core solutions: ProFound AI for cancer detection in 2D and 3D mammography, PowerLook Density Assessment for objective breast density scoring, and ProFound AI Risk for image-based risk evaluation. These solutions are designed to help radiologists find cancers earlier, reduce missed diagnoses, improve workflow efficiency, and personalize breast cancer screening. iCAD's technology is backed by 51 clinical studies across 130 clinical sites and trained on over 20 million images. The company's fourth-generation AI algorithms are FDA cleared, CE marked, and Health Canada licensed, serving customers in 50 countries worldwide. iCAD estimates its technology has been used to read more than 40 million mammograms in the last five years alone, with nearly 30% being tomosynthesis studies. The company partners with leading healthcare systems, imaging centers, technology platforms, and advocacy organizations to improve global access to breast cancer screening and detection.
Company description ICAD official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at ICAD?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer
- Dense breast tissue screening
- Early-stage invasive cancers
- Interval cancers
Who it serves
- Academic Medical Centers
- Breast Imaging Centers
- Health Systems
- Hospitals
- Imaging Centers
- Radiology Groups
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: CancerIQ, Cerner, Densitas, Epic, Google Health, Hologic workstations, Intelerad PACS.
Geographic context
Markets50 countries globally · United States
Company sourceOfficial website
Company milestones
Platform expansion
Acquired by RadNet's DeepHealth subsidiary in July 2025. Expanded partnership with Google Health to enhance technology and expand global access. Partnership with CancerIQ for comprehensive breast health care solution. Over 40 million mammograms read in last 5 years
Partnerships
Recorded partners
- CancerIQ
- Densitas
- Google Health
- Hologic
- Intelerad
- Multiple platform and integration partners
- RadNet/DeepHealth (parent company)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ProFound AI Detection
AI-powered cancer detection for 2D and 3D mammography screening
Software · Cloud SaaSCompany source
ProFound AI Risk
World's first image-based breast cancer risk model, 2.4x more accurate than traditional models
Software · Cloud SaaSCompany source
ProFound Breast Health Suite
Comprehensive AI-powered breast health platform combining Detection, Density, and Risk
Platform · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Effectiveness and Safety of a Self-Management Program for Substance Addiction Consequences: A Pilot Clinical Trial.Substance use & addiction journal · Aug 14, 2026
Applicability of Guideline-Based Aortic Intervention Thresholds in the Indian Population.The Thoracic and cardiovascular surgeon · Jul 30, 2026
Group-based interventions for individuals with dual pathology: a preliminary focus group study.BMC nursing · Jul 8, 2026
Breast area affects the performance of a commercial artificial intelligence algorithm assessment of negative digital breast tomosynthesis exams.European journal of radiology · Jul 1, 2026
Enhanced and selective oxygen reduction by iron porphyrin with a biguanide residue in the second coordination sphere.Chemical science · Jun 18, 2026
Establishing reference values for aortic dimensions in the general Indian population and implications for global standards.Indian journal of thoracic and cardiovascular surgery · May 1, 2026
Clinical validation
Clinical-trial records
Pemafibrate for Symptomatic ICAS RCTNCT07562178 · Mentioned · RECRUITING
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial AtherosclerosisNCT05518305 · Mentioned · RECRUITING
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast DensityNCT05068388 · Mentioned · COMPLETED
Screening Mammography: Single Reading by One Radiologist With AI vs. Double Reading by Two Radiologists (AI-BCSQ)NCT07075679 · Mentioned · RECRUITING
Predicting Stroke Risk in ICAD With Novel MRINCT05515874 · Mentioned · COMPLETED
Application of High-Resolution Magnetic Resonance Vessel Wall Imaging in Endovascular TreatmentNCT07497152 · Mentioned · COMPLETED
Regulatory
Regulatory records
ProFound Detection (V4.0)K240417 · 510k · Nov 8, 2024
PowerLook Density Assessment V4.0K211506 · 510k · Jul 12, 2021
ProFound AI Software V3.0K203822 · 510k · Mar 12, 2021
ProFound AI Software V2.1K191994 · 510k · Oct 4, 2019
PowerLook Tomo Detection V2 SoftwareK182373 · 510k · Dec 6, 2018
PowerLook® Tomo Detection SoftwareP160009 · Pma · Mar 24, 2017
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
20-40% of cancers missed in mammogram screenings
Industry baseline that ProFound aims to reduce
50% reading time reduction
Radiologist workflow efficiency improvement
2.4x more accurate than traditional risk models
ProFound AI Risk vs traditional risk assessment models
99% 5-year survival rate
When breast cancer detected early
Up to 4x elevated risk
Breast density impact on cancer risk
Baptist Health South Florida - Christine E. Lynn Women's Health and Wellness Institute
Elevating accuracy in breast cancer detection with ProFound AI
Cleveland Clinic
Finding breast cancers that radiologists fear the most using ProFound AI
IU Health (Frankfort, Arnett, White Memorial)
ProFound AI helping single readers in radiology centers
Kings County Hospital
Using ProFound AI as a second set of eyes for radiologists
PINK Breast Center
Improved workflow enabling rapid reads and real-time patient results for DBT breast cancer screenings
Radiology Consultants of Iowa (RCI)
First in Iowa to adopt ProFound AI as breast AI solution for mammography
SimonMed Imaging
Using ProFound AI to detect subtle, obscured lesions earlier and improve workflow
Wake Radiology
Implementing ProFound AI for flexible mammogram reading from multiple workstations and PACS
Wooster Community Hospital
Seamless adoption of ProFound AI offering immediate benefits to radiologists and patients with additional efficiencies gained
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Dana Brown
President & CEO
06 · Company updates
Updates from ICAD
Recent articles published on ICAD's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.